Stakeholders Offer Some Hatch-Waxman Creativity, Highlight Limits Of FDA Action
Executive Summary
Other proposals were broad in nature, and did not provide the agency with specific mechanisms to consider.
You may also be interested in...
FDA Looks Ahead To Complex Product-Specific Guidances
The agency offers a glimpse of its regulatory agenda, although several have been carried over through multiple list updates.
Exploring the US FDA's Upcoming Complex Generic Product-Specific Guidance Lists
The agency offers a glimpse of its regulatory agenda, although several have been carried over through multiple list updates.
Was Coronavirus A Factor In Cipla's Albuterol FDA Approval?
The agency said Cipla’s ANDA met all the requirements for approval, but also that there is increased demand for the products.